Immune System News and Research

RSS

Engineered immune cells suppress asthma symptoms in allergic mice

Genetically engineered CAR T cells expressing artificial receptor proteins are increasingly used in the clinic to boost the immune system's response against leukemias and other cancers.

6 Jul 2026

BCG vaccine may remodel the human brain's immune environment

New research led by Mass General Brigham investigators suggests that the Bacillus Calmette-Guérin (BCG) vaccine - which is delivered through the skin to prevent tuberculosis - may remodel the human brain's immune environment, offering a potential biological explanation for previously observed associations between BCG vaccination and lower Alzheimer's disease risk.

6 Jul 2026

Allergies show a small but significant link to later cancer risk

A systematic review and meta-analysis of 28 cohort-based studies found a weak but statistically significant association between allergic diseases and later cancer incidence. The signal was strongest in the Western Pacific region and among people with asthma, but high heterogeneity and limited subgroup evidence mean the findings require caution.

5 Jul 2026

New breast cancer classification system predicts immunotherapy response success

The advent of immune checkpoint inhibitors (ICIs) has marked a paradigm shift in cancer treatment, yet a significant portion of breast cancer patients fail to respond to these therapies.

3 Jul 2026

New AI model improves prediction of cancer immunotherapy success

Cancer immunotherapy drugs known as immune checkpoint inhibitors (ICIs) can be miracle drugs for cancer patients, curing some and turning deadly disease into a manageable chronic condition in others.

3 Jul 2026

Can ibuprofen improve drug-resistant tuberculosis treatment?

While ibuprofen reduced inflammatory markers in drug-resistant TB patients, it did not enhance treatment outcomes, indicating the need for further research.

3 Jul 2026

First-in-class experimental CAR T-cell therapy shows promise against solid tumors

Researchers with the Charbonneau Cancer Institute at the University of Calgary and McMaster University have identified a unique target present on a specific group of solid cancerous tumors.

2 Jul 2026

Engineered CAR T cells show promise against myeloproliferative neoplasms

A new form of CAR T cell therapy has been designed to find and destroy the cancer-driving stem cells responsible for a group of blood cancers known as myeloproliferative neoplasms (MPNs), while leaving healthy blood cells unharmed, in new research led by UCL and University of Oxford researchers.

1 Jul 2026

LEF1 and niche-derived factors regulate T cell stemness across chronic diseases

T cells are an elite fighting force of the immune system, seeking out and destroying diseased cells. But in a prolonged campaign against a chronic condition - like a viral infection, or cancer - the body needs a steady supply of these killer troops.

1 Jul 2026

CAR-T cell therapy shows potential to eliminate aggressive glioblastoma

A study led by a researcher based at King's College London and McMaster University in Canada reveals how CAR-T cell therapy, a treatment that engineers a patient's own immune cells to recognize and attack cancer, could be used to treat glioblastoma.

1 Jul 2026

Alexandre Detappe wins ERC grant for nanomedicine-based cancer immunotherapy

The ERC (European Research Council) Proof of Concept grant awarded to Alexandre Detappe (Gustave Roussy/Institut Strauss/Université Paris-Saclay/Inserm) will fund the Nano-BITE project, which aims to improve the ability of the immune system to fight solid tumors through nanomedicine.

1 Jul 2026

COVID-19 vaccine boosters may protect against future animal coronavirus outbreaks

COVID-19 vaccine boosters not only protect against SARS‑CoV‑2 – the virus behind the most recent pandemic – but may also help protect against some future coronaviruses that risk spreading from animals to humans, Cambridge researchers have shown.

1 Jul 2026

New AI framework outperforms conventional biomarkers in predicting cancer survival

Digestive system cancers, including hepatobiliary and gastrointestinal malignancies, remain a major global oncological burden. Although immune checkpoint inhibitors have changed the treatment landscape for some patients, their overall efficacy remains limited, with only about 15% to 30% of patients achieving durable clinical benefit.

1 Jul 2026